Last reviewed · How we verify
BP1001
At a glance
| Generic name | BP1001 |
|---|---|
| Also known as | Liposomal Grb-2, L-Grb-2, BP-100-1.01 |
| Sponsor | Bio-Path Holdings, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BP1001-A in Patients With Advanced or Recurrent Solid Tumors (PHASE1)
- Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML (PHASE2)
- Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS (PHASE1, PHASE2)
- Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |